Intra-Cellular's shares surged as news suggests J&J may acquire the neuropsych-focused biotech company at a premium of 39%. Intra-Cellular's Caplyta drug for schizophrenia and bipolar disorders, along with potential in depression treatment, boosts its value in the deal.